NASDAQ:GRCE Grace Therapeutics (GRCE) Stock Price, News & Analysis $2.95 -0.02 (-0.67%) As of 05/27/2025 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock About Grace Therapeutics Stock (NASDAQ:GRCE) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Grace Therapeutics alerts:Sign Up Key Stats Today's Range$2.91▼$3.0450-Day Range$1.80▼$3.0452-Week Range$1.75▼$4.97Volume18,354 shsAverage Volume57,705 shsMarket Capitalization$29.91 millionP/E RatioN/ADividend YieldN/APrice Target$12.00Consensus RatingBuy Company OverviewGrace Therapeutics Inc. is a late-stage biopharma company advancing GTx-104, its novel injectable formulation of nimodipine which addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage. Grace Therapeutics Inc., formerly known as Acasti Pharma Inc., is based in Princeton, New Jersey.Read More… Grace Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks56th Percentile Overall ScoreGRCE MarketRank™: Grace Therapeutics scored higher than 56% of companies evaluated by MarketBeat, and ranked 498th out of 920 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingGrace Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageGrace Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Grace Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Grace Therapeutics are expected to grow in the coming year, from ($1.06) to ($0.75) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Grace Therapeutics is -2.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Grace Therapeutics is -2.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGrace Therapeutics has a P/B Ratio of 0.57. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Grace Therapeutics' valuation and earnings. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for GRCE. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGrace Therapeutics does not currently pay a dividend.Dividend GrowthGrace Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for GRCE. News and Social Media4.2 / 5News Sentiment1.55 News SentimentGrace Therapeutics has a news sentiment score of 1.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.03 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Grace Therapeutics this week, compared to 1 article on an average week.Search Interest2 people have searched for GRCE on MarketBeat in the last 30 days. MarketBeat Follows4 people have added Grace Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Grace Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders13.51% of the stock of Grace Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 6.08% of the stock of Grace Therapeutics is held by institutions.Read more about Grace Therapeutics' insider trading history. Receive GRCE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Grace Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address GRCE Stock News HeadlinesThis Grace Therapeutics Insider Increased Their Holding By 12% Last YearMay 25 at 11:21 AM | finance.yahoo.comBiotech Stock Ends Week On High Note Following Bullish Coverage InitiationMay 2, 2025 | msn.comTrump’s Bitcoin Reserve is No Accident…For the first time in history, we have a president who understands crypto's potential to bypass the banking system entirely. And Wall Street's biggest players know it. I've created a blueprint revealing how everyday investors can turn this historic shift into potentially life-changing wealth. Like the 75,000 new millionaires created in the last bull run— only this time with institutional backing.May 28, 2025 | Crypto 101 Media (Ad)Grace Therapeutics Announces Alignment with the FDA Supporting the Planned NDA Submission for GTx-104April 9, 2025 | globenewswire.comGrace Therapeutics files to sell 8.84M shares of common stock for holdersMarch 10, 2025 | markets.businessinsider.comGrace Therapeutics Files Form S-3 for Flexible Securities OfferingMarch 10, 2025 | tipranks.comGrace Therapeutics to Participate in the TD Cowen 45th Annual Health Care ConferenceFebruary 25, 2025 | globenewswire.comGRCE: STRIVE-ON Results ReportedFebruary 21, 2025 | finance.yahoo.comSee More Headlines GRCE Stock Analysis - Frequently Asked Questions How have GRCE shares performed this year? Grace Therapeutics' stock was trading at $3.74 at the start of the year. Since then, GRCE shares have decreased by 21.1% and is now trading at $2.95. View the best growth stocks for 2025 here. How were Grace Therapeutics' earnings last quarter? Grace Therapeutics, Inc. (NASDAQ:GRCE) posted its quarterly earnings results on Thursday, February, 13th. The company reported ($0.26) EPS for the quarter, topping analysts' consensus estimates of ($0.27) by $0.01. Who are Grace Therapeutics' major shareholders? Grace Therapeutics' top institutional shareholders include Nantahala Capital Management LLC (11.62%), ADAR1 Capital Management LLC (3.39%) and Stonepine Capital Management LLC (2.90%). How do I buy shares of Grace Therapeutics? Shares of GRCE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings2/13/2025Today5/28/2025Next Earnings (Estimated)6/20/2025Fiscal Year End3/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:GRCE Previous SymbolNASDAQ:GRCE CIK1444192 Webwww.acastipharma.com Phone818-839-4378Fax45-0687-2272EmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price Target$12.00 High Stock Price Target$12.00 Low Stock Price Target$12.00 Potential Upside/Downside+306.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.16) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$12.85 million Net MarginsN/A Pretax MarginN/A Return on Equity-20.10% Return on Assets-17.10% Debt Debt-to-Equity RatioN/A Current Ratio6.06 Quick Ratio6.06 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.14 per share Price / Book0.57Miscellaneous Outstanding Shares10,140,000Free Float8,770,000Market Cap$29.91 million OptionableN/A Beta0.89 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free Report This page (NASDAQ:GRCE) was last updated on 5/28/2025 by MarketBeat.com Staff From Our PartnersTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredWe’ve Entered the Most Bullish Phase of the CycleIt happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Grace Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Grace Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.